Social Media has become a central communication channel for many pharmaceutical companies. Whether it's a Facebook page, Instagram campaign, or YouTube channel – information about medications, services, and indications is increasingly shared via social networks.
It is often underestimated that with increasing visibility on social media comes increasing regulatory responsibility.
Pharmacovigilance on social media is not an option, but a legal requirement.
This duty to monitor also extends to Social media platforms like Facebook, Instagram, X (formerly Twitter) or YouTube.
However, companies are not responsible for third-party content, but for all channels on which you are active or have influence.
This means that all posts, comments, reactions, and direct messages on the company's own profiles or profiles equivalent to these must be regularly checked for possible indications of adverse drug reactions (AEs).
Social media differs significantly from traditional communication channels – especially with regard to Pharmacovigilance:
Real-time communication around the clock
Comments can appear at any time—even at night or on weekends. A sporadic review isn't enough; continuous monitoring is required.
High interaction density
A single post on Facebook or Instagram can trigger hundreds of comments. Personal experiences are common, especially when it comes to health or product questions – and potentially relevant to PV.
Different formats and channels
On Instagram, people often respond via stories, on YouTube via the comment function, and on Facebook via Messenger. An effective solution must take all of these formats into account.
Public visibility
Statements on social media are often visible to everyone. Overlooking indications of side effects can have not only regulatory but also reputational consequences.
evalii® is a specialized solution to Implementing pharmacovigilance requirements on social media in an automated and legally compliant manner – around the clock, on all relevant platforms.
What evalii® offers:
Automated monitoring of your own social media channels
Whether Facebook, Instagram, X or YouTube, evalii® systematically and continuously scans comments, messages and posts on company profiles.
Recognition of PV-relevant statements
Side effects are identified, classified and marked, even in indirect or colloquial formulations.
Documentation & Compliance
Every find is documented, including timestamp, channel, text excerpt, and processing status – fully auditable and GDPR compliant.
Integration into existing processes
evalii® can be adapted to individual SOPs, role models and approval processes.
Conclusion: Anyone who communicates on social media must also ensure pharmacovigilance
Pharmacovigilance on social media is not just a regulatory obligation – it is a patient safety imperative.
As social media presence grows, so does responsibility. Companies that actively use Facebook, Instagram or other platforms must also Check for PV-relevant content around the clock.
evalii® makes this task not only feasible but also efficient. Social media becomes a channel that is not only informative but also secure.
Do you have any questions about evalii® or feasibility? Please contact us: https://www.cross4channel.de/kontakt/
Interested? Feel free to contact us here – or by WhatsApp:
English 
German